Advertisement Redbiotec, GE Healthcare to advance CMV vaccine development - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Redbiotec, GE Healthcare to advance CMV vaccine development

Switzerland-based biopharmaceutical firm Redbiotec has applied its unique expertise and innovative technology platform to complete a collaborative program with global multinational, GE Healthcare Life Sciences.

Using GE Healthcare’s single-use WAVE Bioreactor and ReadyToProcess crossflow filtration system, the team developed a new process for the production, clarification and concentration of cytomegalovirus-like particles.

Results from the trial have recently been published, further substantiating the value of the Redbiotec rePAX platform to develop and produce new vaccines against cytomegalovirus (CMV).

Redbiotec uses its proprietary rePAX co-expression technology for the efficient generation of multi-component virus-like particles (VLPs) and other protein assemblies.

The technology is effectively applied to both in-house and external co-development programs, supporting the company’s mission to discover and develop new, effective vaccines against the highly prevalent influenza and herpes viruses.

GE Healthcare Life Sciences section manager Cell Culture, LS Bio Process Jakob Liderfelt said the company seeks to collaborate with world-wide biotechnology leaders such as Redbiotec to help drive disease research forward.

"We are looking forward to continuing our work with the company to help advance their CMV program using our next-generation WAVE Bioreactor system," Liderfelt said.

"This system was specifically developed to enable the fast and scalable production of biopharmaceuticals such as Redbiotec’s virus-like particles."

Redbiotec CEO Christian Schaub said the company’s rePAX technology allows them to successfully replicate viral structures or even whole viruses. Importantly, these natural, virus-like particles (reVLPs) are functional but non-replicating, rendering them non-hazardous and allowing us to apply them to vaccine development.

"The vaccine will then stimulate an immune response without causing infectious disease," Schaub said.

"Collaborations such as this project with GE Healthcare enable us to develop CMV-like particles and soluble CMV protein complexes at an industrial scale for the pre-clinical and clinical trials of vaccines."